Prasugrel: A Novel P2Y12 Receptor Inhibitor

Itsik Ben-Dor; Mickey Scheinowitz; Ron Waksman

doi:10.1002/9781444306347.ch9

Prasugrel: A Novel P2Y₁₂ Receptor Inhibitor

Itsik Ben-Dor^*
, Mickey Scheinowitz
, Ron Waksman

^*Corresponding author for this work

School of Biomedical Engineering

Rabin Medical Center Israel
Tel Aviv University
Washington Hospital Center

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Original language	English
Title of host publication	Pharmacology in the Catheterization Laboratory
Publisher	Wiley-Blackwell
Pages	59-66
Number of pages	8
ISBN (Print)	9781405157049
DOIs	https://doi.org/10.1002/9781444306347.ch9
State	Published - 30 Oct 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Antiplatelet therapy monitoring
Joint Utilization of Medication to Block Platelets Optimally-Thrombolysis In Myocardial Infarction (JUMBO-TIMI)
OPTIMUS-3 study and prasugrel standard doses with high loading doses
Percutaneous coronary intervention (PCI) following acute coronary syndrome (ACS)
Prasugrel (CS-747, LY640315)-investigational, third-generation thienopyridine
Prasugrel safety and tolerability in healthy volunteers
Prasugrel, novel p2y12 receptor inhibitor
Thienopyridines-class of ADP/P2Y12 receptor inhibitors
Thrombotic thrombocytopenic purpura (TTP)
VerifyNow point of care assay with light transmission aggregometry (LTA)

Access to Document

10.1002/9781444306347.ch9

Cite this

@inbook{03c2ec207ef34a6aa18173a7fd3a0483,

title = "Prasugrel: A Novel P2Y12 Receptor Inhibitor",

keywords = "Antiplatelet therapy monitoring, Joint Utilization of Medication to Block Platelets Optimally-Thrombolysis In Myocardial Infarction (JUMBO-TIMI), OPTIMUS-3 study and prasugrel standard doses with high loading doses, Percutaneous coronary intervention (PCI) following acute coronary syndrome (ACS), Prasugrel (CS-747, LY640315)-investigational, third-generation thienopyridine, Prasugrel safety and tolerability in healthy volunteers, Prasugrel, novel p2y12 receptor inhibitor, Thienopyridines-class of ADP/P2Y12 receptor inhibitors, Thrombotic thrombocytopenic purpura (TTP), VerifyNow point of care assay with light transmission aggregometry (LTA)",

author = "Itsik Ben-Dor and Mickey Scheinowitz and Ron Waksman",

year = "2009",

month = oct,

day = "30",

doi = "10.1002/9781444306347.ch9",

language = "אנגלית",

isbn = "9781405157049",

pages = "59--66",

booktitle = "Pharmacology in the Catheterization Laboratory",

publisher = "Wiley-Blackwell",

address = "ארצות הברית",

}

TY - CHAP

T1 - Prasugrel

T2 - A Novel P2Y12 Receptor Inhibitor

AU - Ben-Dor, Itsik

AU - Scheinowitz, Mickey

AU - Waksman, Ron

PY - 2009/10/30

Y1 - 2009/10/30

KW - Antiplatelet therapy monitoring

KW - Joint Utilization of Medication to Block Platelets Optimally-Thrombolysis In Myocardial Infarction (JUMBO-TIMI)

KW - OPTIMUS-3 study and prasugrel standard doses with high loading doses

KW - Percutaneous coronary intervention (PCI) following acute coronary syndrome (ACS)

KW - Prasugrel (CS-747, LY640315)-investigational, third-generation thienopyridine

KW - Prasugrel safety and tolerability in healthy volunteers

KW - Prasugrel, novel p2y12 receptor inhibitor

KW - Thienopyridines-class of ADP/P2Y12 receptor inhibitors

KW - Thrombotic thrombocytopenic purpura (TTP)

KW - VerifyNow point of care assay with light transmission aggregometry (LTA)

UR - https://www.scopus.com/pages/publications/84889453692

U2 - 10.1002/9781444306347.ch9

DO - 10.1002/9781444306347.ch9

M3 - ???researchoutput.researchoutputtypes.contributiontobookanthology.chapter???

AN - SCOPUS:84889453692

SN - 9781405157049

SP - 59

EP - 66

BT - Pharmacology in the Catheterization Laboratory

PB - Wiley-Blackwell